Crinetics Pharmaceuticals, Inc.CRNXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | +0.00% | -43.59% | +158.40% | +0.00% |
| Gross Profit Growth | -100.00% | +0.00% | -43.59% | +158.40% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +40.99% | +36.26% | +28.79% | +18.71% | +17.63% |
| Weighted Average Shares Diluted Growth | +40.99% | +36.26% | +28.79% | +18.71% | +17.63% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -39.62% | -9.42% | -22.52% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +46.11% | +125.79% | +39.17% | +37.84% | +27.59% |
| Book Value per Share Growth | +7.86% | +80.35% | +11.28% | +18.79% | +9.42% |
| Debt Growth | +0.71% | -0.01% | -3.21% | -6.34% | -6.46% |
| R&D Expense Growth | +41.21% | +46.04% | +42.93% | +37.63% | +46.13% |
| SG&A Expenses Growth | +67.22% | +65.00% | +70.57% | +100.67% | +101.86% |